Introduction
GLP-1 telehealth is one of the fastest-growing healthcare categories in the country. It is also one of the most heavily scrutinized.
The FTC has moved from warning letters to enforcement orders. The FDA and HHS issued more than 100 cease-and-desist letters to companies running deceptive GLP-1 ads through a single coordinated initiative in the fall of 2025. The window for growth-at-any-cost marketing in this category is closed.
The practices that build durable patient bases from here are not the ones spending the most. They are the ones building marketing programs that are credible, compliant, and strategically disciplined from the start.
This guide explains what that actually looks like in practice, channel by channel.
Key Takeaways
- Enforcement is real and recent: The FTC finalized a consent order against NextMed on December 3, 2025 for hidden costs, fake reviews, and unsubstantiated weight-loss claims. These are common practices, not edge cases.
- Pricing transparency is non-negotiable: Every ad and landing page that leads with a price must clearly disclose what is and is not included. Drug costs, lab fees, and consultation charges must appear before payment is collected.
- Results claims require substantiation: "Lose up to X pounds" is not compliant without competent and reliable scientific evidence reflecting typical outcomes. Creative teams and compliance reviewers need to be aligned before this language goes live.
- Authentic social proof only: Testimonials must come from real patients with real outcomes. Incentivized reviews, fake testimonials, and suppression of negative reviews are now explicit enforcement targets.
- Drug name references carry specific risk: The FDA flagged four specific claim categories in its September 2025 enforcement campaign. Implying equivalence with branded GLP-1 medications or suggesting FDA approval of compounded products are enforcement targets.
- Compliant paid media requires a different infrastructure: Server-side tracking, first-party audience building, and creative that passes both platform review and FTC scrutiny are the standard, not optional upgrades.
- Compliance is a positioning advantage: Practices that lead with transparency, substantiated claims, and visible pricing are differentiating themselves in a market where most competitors are still cutting corners.
- The constraint forces better marketing: Stripping away shortcuts requires earning patient trust through clarity and credibility. That is a more durable growth foundation than urgency-based conversion tactics.
What is the regulatory environment for GLP-1 telehealth marketing in 2026?
The regulatory environment is active, coordinated, and escalating. In July 2025, the FTC filed a complaint against NextMed, a GLP-1 telehealth company, finalizing a consent order on December 3, 2025. The FTC alleged NextMed exploited consumer demand by advertising monthly subscription prices ranging from $138 to $188 without disclosing that those fees excluded the actual drug, lab tests, and physician consultation costs. The company also used fake testimonials, offered Amazon gift cards to users who removed negative reviews, and made weight-loss claims (an average of 53 pounds or 23% of body weight) without evidence supporting typical patient outcomes.
The settlement included a $150,000 penalty and a set of permanent prohibitions that read like a checklist of standard aggressive telehealth marketing practices.
Then on September 9, 2025, President Trump issued a memorandum directing the FDA commissioner and HHS secretary to enforce prescription drug advertising laws and regulations. That same day, the FDA and HHS announced a broad initiative to rein in misleading direct-to-consumer pharmaceutical advertising. Through the remainder of that quarter, the FDA issued more than 40 warning letters and more than 100 cease-and-desist letters to compounding pharmacies and related entities for deceptive advertising, including warning letters to several GLP-1 telehealth providers specifically.
This is not a single enforcement action against one bad actor. It is a coordinated, presidentially directed signal about the standard the entire category is now being held to.
What exactly is the FTC targeting in GLP-1 marketing?
The NextMed case is worth understanding in detail because the violations are not obscure compliance technicalities. They are practices visible across dozens of GLP-1 telehealth programs operating today. Four specific categories drove the enforcement action:
- Hidden pricing: Advertising monthly subscription prices that excluded the actual drug, lab work, and physician consultation costs. The programs also carried costly termination fees that were not disclosed upfront.
- Fake testimonials: Using reviews from people who were not actual patients, and offering Amazon gift cards to users who removed negative reviews from public platforms.
- Unsubstantiated weight-loss claims: Claiming users lost an average of 53 pounds or 23% of their body weight without evidence that reflected typical patient outcomes.
- Undisclosed material terms: Burying commitment periods and cancellation restrictions rather than presenting them clearly before payment was collected.
Three of these four categories, pricing transparency, review integrity, and claims substantiation, are areas where a significant portion of GLP-1 telehealth marketing is currently exposed. If your ads lead with a price that excludes the drug cost, if your testimonials are not from verified patients, or if your results copy is not backed by data, you are operating in the same territory the FTC just enforced.
Bottom Line: The NextMed violations are not outliers. They are common practices. Review your own marketing against each of these four categories before your next campaign goes live.
What does compliant GLP-1 creative actually look like?
The instinct when compliance enters the conversation is to make the marketing safer by making it blander. That is the wrong trade-off, and the practices winning in this market right now are proving it.
Compliant GLP-1 marketing does not lead with drug names. It leads with the patient problem: the frustration of trying and failing with conventional approaches, the difficulty of getting personalized medical attention, the appeal of a supervised program that takes the guesswork out of the process.
It communicates access, clinical supervision, and a structured approach. It does not make specific weight-loss promises. It does not hide costs. It does not manufacture social proof.
Compliant vs. non-compliant GLP-1 creative: what the difference looks like in practice
| Element | Non-Compliant Approach | Compliant Approach |
|---|---|---|
| Pricing | "Plans from $99/month" (drug excluded) | "Plans from $99/month. Medication costs billed separately. See full program pricing." |
| Results Copy | "Lose up to 53 lbs with our GLP-1 program" | "Our medically supervised program is designed to support sustainable weight management" |
| Testimonials | Stock images with fabricated quotes | Verified patient reviews with disclosed relationship |
| Drug References | "Same active ingredient as Ozempic" | No branded drug equivalence claims |
| Cancellation Terms | Hidden in checkout flow | Disclosed prominently before payment |
Bottom Line: Compliant creative is not weaker creative. It is more precise. The constraint of compliance removes shortcuts and requires earning patient confidence through clarity, which is a more durable conversion mechanism than urgency or inflated claims.
How should GLP-1 telehealth practices handle paid media in 2026?
Paid media for GLP-1 telehealth works. It also requires a more deliberate setup than a standard direct-response campaign.
Meta restricts ads that reference health conditions in targeting. Google restricts certain pharmaceutical categories from standard search campaigns. Both platforms layer their own review requirements on top of the FTC and FDA standards your content already has to meet.
The practices that get this right are running a specific type of infrastructure.
Server-side conversion tracking. Standard browser-based pixels can send broader behavioral data to ad platforms than a healthcare advertiser intends to share. Server-side tracking passes only pre-screened, non-PHI conversion signals, such as a form submission confirmation or booking completion, without exposing what the patient was seeking care for. This is not optional for a compliant paid media setup in healthcare.
First-party audience building. Building retargeting audiences from behavioral health signals, page visits tied to specific conditions, or intent signals on health-related content creates compliance risk. Audiences built from first-party data, email lists, CRM records, and verified patient interactions are the safer and more accurate alternative.
Creative that passes two standards simultaneously. Every piece of GLP-1 ad creative needs to clear both the platform review process and FTC scrutiny at the same time. Those two filters are not identical. Building a review process that checks both before launch eliminates the cycle of rejected ads and reactive compliance fixes.
Drug name references carry specific enforcement risk. The FDA's September 2025 warning letters flagged four specific categories of claims as misbranding: stating that a compounded product contains the same active ingredients as an FDA-approved drug, implying equivalence with an FDA-approved counterpart, claiming a compounded drug is "clinically proven" or otherwise efficacious, and implying FDA approval. Any of these four framings in your creative, whether in ad copy, landing pages, or product descriptions, puts your practice in the same territory the FDA has already enforced.
Browser pixel vs. server-side tracking for healthcare paid media
| Factor | Browser-Based Pixel | Server-Side Tracking |
|---|---|---|
| Data Flow | Sends broad browser behavior to third parties | Sends selected events from a controlled server environment |
| Healthcare Risk | Higher on health-related pages without controls | Lower with consent, data minimization, and review |
| Campaign Optimization | Strong signal with potential compliance exposure | Useful signal with stronger control over what is shared |
| Best Use for GLP-1 | Avoid on condition-specific pages | Preferred standard for healthcare paid media |
Bottom Line: Server-side tracking is the minimum standard for compliant GLP-1 paid media. Running standard browser pixels on health-related landing pages creates exposure that no campaign performance justifies.
Does content marketing work for GLP-1 telehealth, and is it worth the investment?
Yes, and it compounds in a way paid media cannot.
GLP-1 telehealth patients rarely convert after seeing one ad. They research the treatment, compare providers, look for clinical credibility, check reviews, and search for answers about the drug, the process, and the practice before they book.
A strong content library captures that research intent at every stage. Condition-specific educational pages, provider-authored blogs, FAQs about the treatment process, and transparent program explainers all do two things simultaneously: they build organic search visibility for the terms your patients are actually using, and they build the clinical credibility that converts a first-time visitor into a booked patient.
For healthcare content specifically, Google's helpful content guidance and E-E-A-T framework reward pages written by qualified people, for real patient questions, with visible author credentials. Provider-authored content, reviewed by a clinician and structured with schema markup, performs better in both traditional search and AI-powered answer engines like Google AI Overviews, ChatGPT, and Perplexity.
GLP-1 content types ranked by compliance risk and search value
| Content Type | Compliance Risk | Search Value | Notes |
|---|---|---|---|
| Provider-Authored Treatment Explainers | Low | High | Builds E-E-A-T, earns AI citations |
| Patient FAQs on the Care Process | Low | High | Captures pre-conversion research intent |
| Program Pricing and Comparison Pages | Medium | High | Requires transparent disclosure throughout |
| Results and Testimonial Pages | High | Medium | Requires verified outcomes and disclosed relationships |
| Drug Name Comparison Pages | High | High | Requires careful FDA/FTC framing |
Bottom Line: Content built around patient questions, written by credentialed providers, and structured for AI answer engines is the lowest-risk, highest-compounding asset a GLP-1 telehealth practice can build.
What infrastructure does a GLP-1 telehealth practice need before scaling marketing?
The most common mistake in GLP-1 telehealth marketing is launching campaigns before the compliance infrastructure underneath them is ready.
A campaign can look functional for a few weeks while the tracking is unsafe, the CRM is misconfigured, the consent management is absent, and the analytics are unreliable. That eventually limits scale, creates liability, and produces data that cannot be trusted for decision-making.
Four components need to be in place first.
HIPAA-aware analytics. Review what data is being collected on your pages, where it goes, and whether health-related browsing behavior is being shared with third parties without appropriate safeguards.
Server-side conversion tracking. Pass only approved, non-PHI conversion events to advertising platforms rather than uncontrolled browser activity. This is the tracking standard for compliant healthcare paid media.
CRM and scheduling platforms with BAA review. Every platform that stores patient information, form submissions, appointment data, or follow-up communications should have a signed Business Associate Agreement in place before patient data flows through it.
Consent management. Users should be clearly informed about tracking, and tracking should fire only in accordance with your legal and privacy requirements. This applies to all pages in the patient acquisition funnel.
Getting this infrastructure right first is not a delay on marketing. It is the foundation that determines whether marketing can scale without creating liability.
Why GLP-1 practices choose Momentum360
Marketing a GLP-1 telehealth practice in 2026 requires more than a media buyer and a copywriter. It needs SEO strategy, compliance-aware tracking infrastructure, healthcare content, conversion-focused design, and paid media management working inside a framework built for the regulatory environment your practice actually operates in.
We have built patient acquisition programs for telehealth and healthcare practices that needed to grow without the compliance exposure. For GLP-1 programs specifically, that means every channel has a clear job, every claim has substantiation behind it, and every campaign is built to pass both platform review and regulatory scrutiny before it goes live.
If your current GLP-1 marketing would not survive the same FTC review that NextMed went through, that is the problem we are built to solve.
Conclusion
The GLP-1 telehealth market is not going away. Patient demand is real, the clinical evidence base is growing, and the addressable opportunity is enormous. But the marketing environment has fundamentally changed.
The FTC has set a clear precedent. The FDA and HHS have signaled broad, presidentially directed enforcement intent. The practices that will build durable patient bases in this market are the ones treating compliance as a foundation for marketing, not a constraint on it.
Transparent pricing, substantiated claims, authentic social proof, and a paid media infrastructure built for the healthcare environment are not risk management measures. They are the positioning of a practice that intends to be in business in five years.
Build to that standard. The practices already doing it are not just avoiding enforcement. They are winning patients who trust them because of the transparency, not despite it.
